Shiraz University of Medical Sciences
Middle East Journal of Cancer
2008-6709
6
1
2015
01
01
Ovarian Cancer Risk Factors in a Defined Population Using Rare Event Logistic Regression
1
9
41980
EN
Elham
Haem
Department of Biostatistics, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran
Seyyed Taghi
Heydari
Research Center for Social Determinants of Health, Jahrom University of Medical Sciences, Jahrom, Iran
Health Policy Research Center, Shiraz University of Medical Sciences, Shiraz, Iran
0000-0001-7711-1137
Najaf
Zare
Department of Biostatistics, Research Center of Fertility and Infertility, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran
Kamran
Lankarani
Health Policy Research Center, Shiraz University of Medical Sciences, Shiraz, Iran
Esmat
Barooti
Ministry of Health and Medical Education, Women’s Affairs Office, Tehran, Iran
Farkhondeh
Sharif
Faculty of Nursing and Midwifery, Shiraz University of Medical Sciences, Shiraz, Iran
Journal Article
2014
04
09
Background: This study evaluated the role of family history of cancer and gynecologic factors in relation to the etiology of ovarian cancer in a low socioeconomic population in Iran.Methods: From 2007-2009 we conducted a screening program on women with insurance coverage provided by the Imam Khomeini Relief Foundation. A total of 26788 women participated in this study of whom 76 cases had ovarian cancer and 26712 were considered as controls. We used rare event logistic (ReLogit) regression analysis with a prior correction method that used the Zelig package in R to obtain odds ratio estimates and confidence intervals.Results: Ovarian cancer was more frequent among postmenopausal than premenopausal (odds ratio: 2.30; confidence interval: 1.17-4.49) women. We observed increased risk for this disease in women with histories of hormone replacement therapy compared to those with no history (odds ratio: 2.36; confidence interval: 1.13-4.91). A greater increase in ovarian cancer was observed in women with family histories of breast (odds ratio: 2.88; confidence interval: 1.44-5.77), ovarian (odds ratio: 11.27; confidence interval: 5.63-22.54) and all cancer sites (odds ratio: 2.95; confidence interval: 1.71-5.08). However, the use of oral contraceptive pills was significantly associated with lower risk for ovarian cancer (odds ratio: 0.47; confidence interval: 0.28-0.79). There was no association between ovarian cancer and age, marital status, occupation, education level, age at menarche, age at first pregnancy and number of pregnancies.Conclusion: Ovarian cancer was considered a rare event. Thus we deemed it necessary to explore the associated risk factors using ReLogit with a prior correction method. The risk factors for ovarian cancer were menopause, history of hormone replacement therapy and family history of cancer of the breast, ovaries and other sites. Oral use of contraceptive pills showed a protective effect on risk for ovarian cancer.
https://mejc.sums.ac.ir/article_41980_1a434b8a4d7bfefcfcdc18e1a2096bc8.pdf
Shiraz University of Medical Sciences
Middle East Journal of Cancer
2008-6709
6
1
2015
01
01
A Molecular Case-Control Study on the Association of Melatonin Hormone and rs#10830963 Single Nucleotide Polymorphism in its Receptor MTNR1B Gene with Breast Cancer
11
20
41982
EN
Nadia A
Abd El Moneim
Department of Cancer Management and Research, Medical Research Institute, University of
Alexandria, Alexandria, Egypt
Hisham El
Masry
Department of Biotechnology, Institute of Graduate Studies and Research, University of
Alexandria, Alexandria, Egypt
Mina Mamdouh
Sorial
Department of Biotechnology, Institute of Graduate Studies and Research, University of
Alexandria, Alexandria, Egypt
Taha I
Hewala
Radiation Science Department, Medical Research Institute, University of Alexandria,
Alexandria, Egypt
0000-0003-1211-0445
Amira
Embaby
Department of Biotechnology, Institute of Graduate Studies and Research, University of
Alexandria, Alexandria, Egypt
Salah
Sheweita
Department of Biotechnology, Institute of Graduate Studies and Research, University of
Alexandria, Alexandria, Egypt
Journal Article
2014
05
15
Background: The main function of the pineal hormone melatonin which is mediated via its two receptors, MTNR1A and MTNR1B, is to mediate dark signals in addition to anti-oxidation, immune system enhancement, protection from radiation, and anti-cancer functions. A common single nucleotide polymorphism in the MTNR1B gene is rs#10830963, which is well known as a risk factor for type 2 diabetes mellitus. This study intends to figure out the role of melatonin and its receptor MTNR1B gene rs#10830963 polymorphism in breast cancer incidence, diagnosis and prognosis.Methods: This study included 43 females with breast cancer and 45 apparently normal healthy females. Restriction fragment length polymorphism-PCR was used for amplification and genotyping of the MTNR1B gene rs#10830963 polymorphism in whole blood. Serum melatonin levels were measured using a ready-for-use radioimmunoassay kit. Results: For the MTNR1B gene rs#10830963 polymorphism, we observed a significantly higher GG genotype frequency among cases (72.1%) than controls (13.3%), with a diagnostic sensitivity of 83.78% and specificity of 76.47%. The cases had a frequency of 11.6% for the CC genotype and 16.3% for the CG genotype which was significantly lower compared to controls that had a 44.4% frequency of the CC genotype and 42.2% frequency of the CG genotype. The GG genotype had a significant association with larger tumor volume (P=0.048). Serum melatonin levels were significantly lower among breast cancer patients than controls. Using the ROC curve analysis, serum melatonin showed a significant AUC (72.6%, P39.5 pg/ml.Conclusion: The risk for breast cancer incidence increased as the serum levels of melatonin decreased and in females homozygous for the G allele (GG genotype) of the MTNR1B gene rs#10830963 polymorphism. The GG genotype was found to be associated with increased breast tumor volume as a marker of a poor prognosis breast cancer.
https://mejc.sums.ac.ir/article_41982_7b6c4c1857ec815b5e46055abeff37c8.pdf
Shiraz University of Medical Sciences
Middle East Journal of Cancer
2008-6709
6
1
2015
01
01
Concurrent Boost with Adjuvant Breast Hypofractionated Radiotherapy and Toxicity Assessment
21
27
41983
EN
Mona M.
Sayed
Department of Radiation Oncology, South Egypt Cancer Institute, Assiut University, Assiut, Egypt
Mohamed I.
El-Sayed
Department of Radiation Oncology, South Egypt Cancer Institute, Assiut University, Assiut, Egypt
Alia M.
Attia
Department of Radiation Oncology, South Egypt Cancer Institute, Assiut University, Assiut, Egypt
Mostafa E.
Abdel-Wanis
Department of Radiation Oncology, South Egypt Cancer Institute, Assiut University, Assiut, Egypt
Journal Article
2014
05
10
Background: The use of shorter radiotherapy schedules has an economic and logistic advantage for radiotherapy departments, as well as a high degree of patient convenience. The aim of this study is to assess the acute and short-term late toxicities of a hypofractionated radiotherapy schedule with a concomitant boost.Methods: We enrolled 57 eligible patients as group A. These patients received 42.5 Gy in 16 fractions of 2.66 Gy each to the whole breast over 3.2 weeks. A concomitant electron boost of 12 Gy in 16 fractions was also administered which gave an additional 0.75 Gy daily to the lumpectomy area for a total radiation dose of 54.5 Gy. Toxicity was recorded at three weeks and at three months for this group as well as for a control group (group B). The control group comprised 76 eligible patients treated conventionally with 50 Gy to the whole breast over five weeks followed by a sequential electron boost of 12 Gy in 2 Gy per fraction.Results: There were no statistically significant differences observed in the incidence of acute skin toxicity, breast pain, and edema recorded at three weeks or pigmentation and fibrosis recorded at three months between the two groups (P0.05).Conclusion: The results of this study suggest there are no increased acute and short- term late toxicities affiliated with the hypofractionated schedule plus a concomitant boost as prescribed compared to the conventional fractionation of adjuvant breast radiotherapy. Large randomized trials and long-term follow-up are needed to confirm these favorable findings.
https://mejc.sums.ac.ir/article_41983_f4b96ba13ceb0424a993af1f6c3f1c0c.pdf
Shiraz University of Medical Sciences
Middle East Journal of Cancer
2008-6709
6
1
2015
01
01
Immunohistochemical Expression of P53 and Ki-67 in Different Histopathological Variants of Basal Cell Carcinoma
29
34
41985
EN
Rasoul
Esmaeili
Student's Research Committee, School of Medicine, Hamadan University of Medical
Sciences, Hamadan, Iran
Masoud
Seyedin Khorasani
Molecular Medicine Department, Biotechnology Research Center, Pasteur Institute of
Iran, Tehran, Iran
Alireza
Monsef
Department of Pathology, Hamadan University of Medical Sciences, Hamadan, Iran
Journal Article
2014
05
15
Background: Basal cell carcinoma is the most common form of skin cancer in men. Increased marker expressions of apoptosis and cell proliferation have been found in the majority of basal cell carcinomas. Our purpose was to determine whether any correlation between immunohistochemical expressions of P53 and Ki-67 in different histopathological variants of basal cell carcinoma and patient’s age, gender and tumor localization existed.Methods: We evaluated basal cell skin specimens obtained from 100 previously diagnosed cases of basal cell carcinoma at the Dermatology Clinic of Farshchian Hospital, Hamadan, Western Iran. At first the specimens were fixed by formalin and stained by hematoxylin-eosin. Histopathological types of the tumor were determined. Immunohistochemical expressions of Ki- 67and P53 were examined. Clinical features of the patients such as age, gender, and lesion site were collected from their files.Results: The specimens were obtained from 62 (62%) men and 38 (38%) women with an age range of 22-107 years. Of basal cell carcinoma specimens, 76% expressed P53 and 60% expressed Ki-67. There was strong staining intensity of P53 protein in 70% and Ki-67 antigen in 30% of specimens. Strong staining intensity of Ki-67 in patients of lower ages was significantly correlated. There was no statistically significant correlation between these markers and other variables (P>0.05).Conclusion: This study highlighted the value of P53 and Ki-67 markers in basal cell carcinoma. We did not observe any significant difference between the histopathological types based on the P53 and Ki-67 expressions and their staining intensities.
https://mejc.sums.ac.ir/article_41985_017079d3cc0f2b6ceb0f2ef3bd7aef8e.pdf
Shiraz University of Medical Sciences
Middle East Journal of Cancer
2008-6709
6
1
2015
01
01
Rate and Time of Ovarian Function Restoration in Menopausal Breast Cancer Patients Who Received Letrozole Following Chemotherapy
35
42
41986
EN
Shapour
Omidvari
Department of Radiation Oncology, Nemazee Hospital, Shiraz University of Medical
Sciences, Shiraz, Iran
0000-0003-3656-9891
Samira
Razzaghi
Student Research Committee, Nemazee Hospital, Shiraz University of Medical Sciences, Shiraz, Iran
Ali
Zamani
Endocrinology Research Center, Department of Internal Medicine, Shiraz University of
Medical Sciences, Shiraz, Iran
Hamid
Nasrolahi
Department of Radiation Oncology, Nemazee Hospital, Shiraz University of Medical
Sciences, Shiraz, Iran
Sayed Hasan
Hamedi
Student Research Committee, Nemazee Hospital, Shiraz University of Medical Sciences, Shiraz, Iran
0000-0002-2050-5909
Ahmad
Mosalaei
Shiraz Institute for Cancer Research, Shiraz University of Medical Sciences, Shiraz, Iran
0000-0002-3986-8865
Niloofar
Ahmadloo
Department of Radiation Oncology, Nemazee Hospital, Shiraz University of Medical
Sciences, Shiraz, Iran
0000-0003-3178-8577
Mansour
Ansari
Department of Radiation Oncology, Nemazee Hospital, Shiraz University of Medical
Sciences, Shiraz, Iran
0000-0002-8249-1776
Saeedeh
Pourahmad
Department of Biostatistics, Medical School, Shiraz University of Medical Sciences, Shiraz, Iran
Mohammad
Mohammadianpanah
Colorectal Research Center, Shiraz University of Medical Sciences, Shiraz, Iran
0000-0001-9391-8977
Journal Article
2014
06
08
Background: The present study aimed to investigate the rate and time of ovarian function restoration in breast cancer patients between 40 and 60 years of age who were in menopause (biochemically documented) and received letrozole after chemotherapy. We intended to further clarify the management strategy for breast cancer patients with different menopausal status.Methods: We prospectively measured the effects of replacing tamoxifen with letrozole on ovarian function recovery in 90 women from two age groups (40-50 and 51-60 years). All had breast cancer and were treated by chemotherapy. Patients had laboratory documentation of menopause (FSH >40 mIU/ml and estradiol <20 pg/mL). Patients did not have menstruation for at least one year. Study patients received letrozole. At three month intervals, we checked their FSH and estradiol levels.Results: At three months after beginning letrozole, 12 patients in the younger age group had laboratory ovarian function restoration, among which three had vaginal bleeding. In the older group, 8 patients had increased estradiol levels; however, there was no evidence of vaginal bleeding in this group. At 6, 9 and 12 months, no ovarian function restoration was seen in the older group. However in younger patients, 4 had laboratory evidence of ovarian function restoration at 6 months, 2 at 9 months and 1 patient showed laboratory ovarian function restoration at 12 months of follow-up. Totally, there was a significant difference in the occurrence of ovarian function restoration between the two groups (P=0.03).Conclusion: A remarkable portion of women with chemotherapy-induced amenorrhea may develop ovarian function restoration. Therefore, endocrine therapy using aromatase inhibitors in patients with chemotherapy-induced amenorrhea should be followed by a regular hormonal study.
https://mejc.sums.ac.ir/article_41986_4bff129bb59cb007f6f0d64a1eb5ae5f.pdf
Shiraz University of Medical Sciences
Middle East Journal of Cancer
2008-6709
6
1
2015
01
01
ST6Gal1, Cox-2 and HB-EGF mRNA Expression in Breast Cancer Samples from Kashan, Iran
43
50
41987
EN
Aliakbar
Taherian
Kashan Anatomical Research Center, Kashan University of Medical Sciences, Kashan, Iran
Seyed Mostafa
Mostafavi Zadeh
Graduate Student, Microbiology Department, Isfahan University of Medical Sciences,
Isfahan, Iran
Hossein
Ghani
Department of Internal Medicine, Kashan University of Medical Sciences, Kashan, Iran
Tahere
Khamechian
Kashan Gametogenesis Research Center, Kashan University of Medical Sciences,
Kashan, Iran
Journal Article
2014
05
27
Background: ST6Gal1, Cox-2 and HB-EGF genes are involved in different tumors and their enhanced expressions often correlate with poor prognosis. In this study we assay the expressions of these genes by reverse transcriptase-PCR in 54 breast cancer samples.Methods: Tissue samples were either formalin-fixed for histopathological examination or frozen for reverse transcriptase-PCR. Image program was used for the densitometry of the image of the gels and the expression of different genes was normalized with beta actin expression. The student's t-test and correlation matrix were used for data analyses.Results: We observed significantly higher expressions of ST6Gal1 (P= 0.040), Cox- 2 (P= 0.001) and HB-EGF (P= 0.009) in the tumor region compared to the margin samples. A significant correlation was found between HB-EGF and Cox-2 expression (P= 0.001). There was a positive correlation between total score, tumor size, histology grade and nuclear grade but there was a reverse correlation between age and tumor size, histology grade and total score. Conclusion: Expressions of ST6Gal1, Cox-2 and HB-EGF in breast tumor samples in this and a number of other studies emphasize their role as important markers in breast cancer . The use of medications to inhibit either their individual expressions or the possible inhibition of all three genes may improve patient survival and prevent metastasis.
https://mejc.sums.ac.ir/article_41987_a906c439f5fae13c09755718106957f0.pdf
Shiraz University of Medical Sciences
Middle East Journal of Cancer
2008-6709
6
1
2015
01
01
A Desmoplastic Small Round Cell Tumor in a Twenty-Eight Year-old Adult Male Presenting with Urological Symptoms
51
56
41976
EN
Amr
Idris
Syrian Private University, Damascus Hospital, Damascus, Syrian Arab Republic
Journal Article
2014
04
07
A desmoplastic small round cell tumor is a malignant tumor of the abdominal and pelvic cavities. This tumor involves serosal surfaces such as the peritoneum, pleura, and scrotum. In this case report a 28-year old male presented with a desmoplastic small round cell tumor located in the abdomen along with urological symptoms. When the diagnosis was completed, the patient’s tumor had metastasized to the liver and retroperi- toneal lymph nodes. This case not only has exemplified that this tumor is rare and fatal but its prompt diagnosis is critical. However it is most likely that the diagnosis of this tumor is found when it has metastasized and this is unfortunately very late.
https://mejc.sums.ac.ir/article_41976_c4b1ea27f0ae69306ffbfd7e5ee7d7df.pdf
Shiraz University of Medical Sciences
Middle East Journal of Cancer
2008-6709
6
1
2015
01
01
IgA Myeloma, Portal Hypertension and Normal Skeletal Survey—A Triad
57
60
41981
EN
Waseem Raja
Dar
Department of Internal Medicine, SKIMS, Srinagar, India
Journal Article
2014
05
09
Multiple myeloma is a neoplastic plasma cell dyscrasia. Patients usually present with bone pain, anemia, hypercalcemia and renal failure. Unusual presentations include progressive bilateral carpal tunnel syndrome, polyarthritis, amyloidosis of the tongue, and involvement of pulmonary parenchyma. Early diagnosis is important for timely therapy. We present the case of a patient with clinical features of portal hypertension that ultimately proved to be multiple myeloma.
https://mejc.sums.ac.ir/article_41981_0941150ff5af9dd117eb8ecd342c7946.pdf
Shiraz University of Medical Sciences
Middle East Journal of Cancer
2008-6709
6
1
2015
01
01
Unilateral Malignant Pleural Effusion as an Initial Manifestation of Acute Lymphoblastic Leukemia: A Rare Case Report
61
64
41984
EN
Sonia
Chabbra
Pathology Department, PGIMS, Rohtak, India
Rajneesh
Kalra
Pathology Department, PGIMS, Rohtak, India
Shivani
Malik
Pathology Department, PGIMS, Rohtak, India
0000-0002-1319-951X
Sunita
Singh
Pathology Department, PGIMS, Rohtak, India
Gurpreet
Singh
Pathology Department, PGIMS, Rohtak, India
Pansi
Gupta
Pathology Department, PGIMS, Rohtak, India
Rajeev
Sen
Pathology Department, PGIMS, Rohtak, India
0000-0001-7957-5613
Journal Article
2014
06
14
Unilateral malignant pleural effusion as an initial manifestation that leads to the diagnosis of an underlying acute lymphoblastic leukemia is a rare event. Early and accurate diagnosis of this case is important for prompt and adequate therapy. We present the case of an18-year-old male who presented to the emergency department with severe respiratory distress. Chest X-ray revealed a unilateral massive right-sided pleural effusion. Cytological examination of the pleural fluid led to the diagnosis of underlying acute lymphoblastic leukemia. Subsequent hemogram, bone marrow aspirate and flow cytometry analysis confirmed the diagnosis of T-lineage acute lymphoblastic leukemia. The patient underwent induction chemotherapy which led to significant clinical improvement due to resolution of the pleural effusion. The patient is on follow up at present. This case report exemplifies and highlights the importance of cytopathological analysis of body cavity fluids in the diagnosis of underlying unsuspected malignancies.
https://mejc.sums.ac.ir/article_41984_cf20956e8f750a22ca91ee9833313e57.pdf
Shiraz University of Medical Sciences
Middle East Journal of Cancer
2008-6709
6
1
2015
01
01
Testicular Epidermoid Cyst
65
66
41979
EN
Bita
Geramizadeh
Transplant Research Center, Shiraz University of Medical Sciences, Shiraz, Iran
0000-0002-4867-5686
Shahrzad
Yazdanpanah
Department of Pathology, Shiraz University of Medical Sciences, Shiraz, Iran
Ali
Aryafar
Department of Surgery, Shiraz University of Medical Sciences, Shiraz, Iran
Journal Article
2014
08
01
https://mejc.sums.ac.ir/article_41979_2b96ebfcbfc595d00b6501de1731d56d.pdf
Shiraz University of Medical Sciences
Middle East Journal of Cancer
2008-6709
6
1
2015
01
01
Metronomic Chemotherapy as a New Strategy for End-stage Pediatric Oncology Patients in Iran
67
69
41977
EN
Mahdi
Shahriari
Pediatric Hematology-Oncology Division, Department of Pediatrics, Shiraz University of
Medical Sciences, Shiraz, Iran
0000-0001-5104-9590
Babak
Abdolkarimi
Pediatric Hematology-Oncology Division, Department of Pediatrics, Shiraz University of
Medical Sciences, Shiraz, Iran
0000-0002-6751-3949
Journal Article
2014
05
12
https://mejc.sums.ac.ir/article_41977_608d4f2eeb2fcea2e8dc47d6be7ace83.pdf
Shiraz University of Medical Sciences
Middle East Journal of Cancer
2008-6709
6
1
2015
01
01
Calendar of Events
70
70
41978
EN
Journal Article
2015
01
07
https://mejc.sums.ac.ir/article_41978_6b9b1b0a80604c8557f5670d20c574e4.pdf